Showing results (1-10 of 162) with videos related to
Sort By:
Pageof 17
Journal for Immunotherapy of Cancer|June 17, 2024
Hypothesis: AdAPT-001 and pseudoprogression - when seeing is not necessarily believingAnthony Conley, Christopher Larson, Bryan Oronsky, et al.Journal for Immunotherapy of Cancer|October 26, 2024
TGF-β trap of AdAPT-001 turns up the heat on tumors and turns down checkpoint blocker resistanceTony R Reid, Bryan Oronsky, Jeannie Williams, et al.Clinical Colorectal Cancer|December 18, 2022
ROCKET: Phase II Randomized, Active-controlled, Multicenter Trial to Assess the Safety and Efficacy of RRx-001 + Irinotecan vs. Single-agent Regorafenib in Third/Fourth Line Colorectal CancerTony R Reid, Nacer Abrouk, Scott Caroen, et al.Oncotarget|August 18, 2015
Going viral: a review of replication-selective oncolytic adenovirusesChristopher Larson, Bryan Oronsky, Jan Scicinski, et al.Life Sciences in Space Research|November 6, 2022
RRx-001 and the "Right stuff": Protection and treatment in outer spaceBryan Oronsky, Scott Caroen, Nacer Abrouk, et al.Recent Patents on Biotechnology|January 13, 2023
Patent and Marketing Exclusivities 101 for Drug DevelopersBryan Oronsky, Scott Caroen, Franck Brinkhaus, et al.Journal for Immunotherapy of Cancer|December 22, 2023
Commentary on oncolytic viruses: past, present, and futureChristopher Larson, Bryan Oronsky, Tony R ReidClinical and Translational Science|June 29, 2023
Data Management 101 for drug developers: A peek behind the curtainBryan Oronsky, Erica Burbano, Meaghan Stirn, et al.Neoplasia (New York, N.Y.)|October 18, 2015
Confirmatory Trials in the Evaluation of Anticancer Medicinal Products in Man--PFS2: A Measure of Therapeutic Action-At-A-DistanceBryan Oronsky, Corey A Carter, Tony R Reid, et al.Oncoimmunology|September 20, 2018
A practical guide to the handling and administration of personalized transcriptionally attenuated oncolytic adenoviruses (PTAVs)Christopher Larson, Bryan Oronsky, Gina Varner, et al.Pageof 17